Sliding Cupping Therapy Matches NBUVB in Psoriasis Severity Reduction at 8 Weeks
Photo by rosario janza / Unsplash
Key Takeaway
Consider sliding cupping as an alternative to NBUVB for plaque psoriasis with similar efficacy.
This randomized controlled trial evaluated the efficacy of sliding cupping therapy compared to narrowband ultraviolet B (NBUVB) therapy in 60 patients with plaque psoriasis. Participants were randomized to receive either sliding cupping or NBUVB treatment three times per week for eight weeks. The primary endpoint was the percentage reduction in Psoriasis Area and Severity Index (PASI) score at week 8. Results showed a mean percentage reduction in PASI of 62.4% (95% CI, 54.9-69.8) in the sliding cupping group and 66.9% (95% CI, 59.6-74.2) in the NBUVB group, with no significant difference between the groups (P=.526). Secondary endpoints, including Physician's Global Assessment (PGA), body surface area, and quality of life measures, also showed no significant differences between the groups at weeks 0, 4, 8, and 12. The total response rates were 69.23% for sliding cupping and 79.17% for NBUVB, which was not statistically significant (P=.526). Safety profiles were similar between the two treatments, with no significant adverse events reported. These findings suggest that sliding cupping therapy may be a viable alternative to NBUVB for managing plaque psoriasis, offering similar efficacy and safety.
More on Psoriasis
Systematic review shows regional differences in HS comorbidity prevalence across North America, Europe, and Asia.
Regional differences in health risks for hidradenitis suppurativa patients
This systematic review and meta-analysis examines the prevalence of hidradenitis suppurativa-associated comorbidities across North America, …
A meta-analysis reveals how hidradenitis suppurativa patients in North America, Europe, and the Middle East/Asia face different odds for dia…
Narrative review discusses ginsenosides for skin conditions including psoriasis and dermatitis with noted evidence gaps.
Review of ginsenosides for skin conditions shows weak evidence and low absorption.
This narrative review examines the use of ginsenosides for various skin conditions, including psoriasis, dermatitis, photoaging, chronic non…
A review of ginsenosides for skin issues like psoriasis and melanoma found the evidence is insufficient and absorption is low.
Herring roe oil reduces inflammatory biomarkers in mild-to-moderate psoriasis
Herring roe oil may lower inflammation in psoriasis
In a randomized controlled trial post hoc analysis of 64 patients with mild-to-moderate psoriasis, oral herring roe oil supplementation for …
A small trial found that herring roe oil reduced several blood-based inflammation markers in people with mild-to-moderate psoriasis over 26 …
Secukinumab improves skin response in Chinese patients with psoriatic arthritis
Secukinumab linked to skin improvement in Chinese psoriatic arthritis patients
This observational cohort study of 446 Chinese patients with psoriatic arthritis found that treatment with secukinumab for over 12 weeks was…
In Chinese psoriatic arthritis patients, secukinumab treatment was associated with significant skin improvement and better quality of life o…
View Original Abstract ↓
BACKGROUND: The sliding cupping therapy represents a traditional Chinese medicine therapy and receives much appreciation for treating plaque psoriasis. This study was designed to test the hypothesis that sliding cupping therapy is non-inferior to narrowband ultraviolet B (NBUVB) therapy in improving disease severity in patients with plaque psoriasis.
METHODS: This prospective study recruited 60 patients with plaque psoriasis who were randomized to receive either sliding cupping intervention or NBUVB treatment. The cup was moved 30 times for each skin lesion until the target skin area turned purple. The initial dose (mJ/cm2) of ultraviolet radiation b (UVB) was determined based on sun-reactive skin types I through VI, which ranged from 300 mJ/cm2 to 800 mJ/cm2. Both treatments were performed 3 times per week for 8 weeks. The primary endpoint was the percentage reduction in Psoriasis Area and Severity Index (PASI) score at week 8, with secondary endpoints, including Physician's Global Assessment (PGA), body surface area, visual analogue scale scores, and quality of life measures.
RESULTS: The total response rates were 69.23% (18/26) and 79.17% (19/24) for patients receiving sliding cupping intervention and those receiving NBUVB treatment, respectively, which showed no significant difference (P = .526). The PASI scores, body surface area, and PGA were reduced in patients with plaque psoriasis at W0, W4 and W8 after either sliding cupping intervention or NBUVB treatment (P <.001), and these reductions were not significantly different between the patients receiving sliding cupping intervention and those receiving NBUVB treatment at W0, W4, W8, and W12. At W8, the mean percentage reduction in PASI was 62.4% (95% CI, 54.9-69.8) in the sliding cupping group and 66.9% (95% CI, 59.6-74.2) in the NBUVB group, with no significant difference between groups. The total response rates were 69.23% (18/26) and 79.17% (19/24), respectively (P = .526). Patients receiving sliding cupping intervention and those receiving NBUVB treatment did not show statistically significant differences in these outcomes at W0, W4, W8, and W12 (P >.05).
CONCLUSION: The overall results suggest that sliding cupping therapy exhibits statistically similar efficacy and safety profiles as NBUVB treatment, especially at 8 weeks after treatment.
Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment
Study checks how well pain scores track joint damage in psoriatic arthritis patients
Related in Dermatology
Tralokinumab maintains efficacy in adults with moderate-to-severe atopic dermatitis up to 152 weeks
Tralokinumab keeps skin clear for up to four years in adults
This post hoc interim analysis of the ECZTEND open-label extension trial evaluated adults with moderate-to-severe atopic dermatitis who comp…
New data shows a specific eczema drug keeps skin clear for up to four years in adults who need long-term relief.
Brodalumab Improves Palmoplantar Pustulosis in Japanese Adults in Phase 3 Trial
Brodalumab shows benefit for palmoplantar pustulosis in Japanese adults
This randomized Phase 3 trial in Japanese adults with palmoplantar pustulosis found that brodalumab 210 mg improved PPPASI scores similarly …
A Phase 3 trial found brodalumab improved skin scores for palmoplantar pustulosis in Japanese adults, though infection risks were frequent.
5-Fluorouracil and MAL-PDT vs Surgery for Bowen's Disease: 4-Year Outcomes
Surgery kept skin cancer away better than two light-based treatments in this trial.
This multicenter RCT compared 5-fluorouracil, methylaminolevulinate photodynamic therapy (MAL-PDT), and surgical excision (SE) in 250 patien…
Surgery offered the highest chance of staying cancer-free for four years, while light-based treatments showed lower success rates in this st…
Ixekizumab shows efficacy in children with enthesitis-related and juvenile psoriatic arthritis
New drug ixekizumab shows promise for children with arthritis
This multicentre, open-label, phase 3 study evaluated ixekizumab in 101 children with enthesitis-related arthritis or juvenile psoriatic art…
A phase 3 study found ixekizumab helped many children with arthritis meet response criteria at week 16, with mostly mild side effects report…
From Other Specialties
Nicotinic partial agonists show no effect on opioid use in HIV-positive smokers
New data on nicotine treatment for HIV patients who use opioids
This secondary analysis of a randomized trial in 97 HIV-positive smokers with risky alcohol use and baseline opioid use found no significant…
A new look at nicotine treatment for HIV patients who use opioids found no difference in opioid use between two drug groups.
CRS3123 shows efficacy in phase 2 trial for Clostridioides difficile infection
Early trial shows CRS3123 matches vancomycin for treating C. diff infection
This phase 2 randomized trial compared CRS3123 with vancomycin in 43 adults with CDI. Clinical cure rates were similar across groups, but re…
A small Phase 2 trial found CRS3123 worked as well as vancomycin for curing C. diff infection in adults with their first episode or recurren…
Valacyclovir No Better Than Placebo for Stromal Keratitis in Herpes Zoster Ophthalmicus
Oral antivirals do not prevent eye inflammation in shingles patients
This secondary analysis of a randomized trial in 527 patients with herpes zoster ophthalmicus found that oral valacyclovir 1 g daily did not…
A study of 527 people with shingles eye infections found oral antivirals did not stop inflammation. Close monitoring and low-potency steroid…
Positive in vitro interactions with β-lactam linked to lower 14-day mortality in MRSA bacteraemia
Positive lab interactions linked to lower early death in MRSA infection treatment
This post hoc analysis of a multicentre randomized trial included 150 adults with MRSA bacteraemia. Positive in vitro interactions between v…
When lab tests showed bacteria died better with combined drugs, patients had lower early death rates. This finding suggests smarter drug pai…